BRIEF published on 05/13/2025 at 07:35, 1 year 4 months ago Poxel's First Quarter 2025 Revenue and Business Developments Regulatory Approval Corporate Strategy Poxel Revenue TWYMEEG® Sales Royalties Increase
PRESS RELEASE published on 05/13/2025 at 07:30, 1 year 4 months ago Inside Information / Information on annual revenues Poxel reports consolidated revenue and corporate updates for Q1 2025, with TWYMEEG® sales growth in Japan and regulatory approval for diabetic patients with renal impairment Revenue Regulatory Approval Japan Poxel TWYMEEG
BRIEF published on 03/20/2025 at 21:50, 1 year 6 months ago Poxel Releases Positive Preclinical Results for HCM Treatment Preclinical Study Hypertrophic Cardiomyopathy PXL065 Myocardial Remodeling Cardiac Fibrosis
PRESS RELEASE published on 03/20/2025 at 21:45, 1 year 6 months ago Inside Information / Other news releases Poxel announces positive preclinical study results for PXL065, a potential treatment for Hypertrophic Cardiomyopathy, showing benefits in a mouse model Preclinical Study Poxel Hypertrophic Cardiomyopathy PXL065 Mouse Model
BRIEF published on 02/11/2025 at 20:33, 1 year 7 months ago Poxel Holds Combined General Meeting, Announces Key Results General Meeting Shareholder Voting Financial Delegations Remuneration Policy Poxel SA
PRESS RELEASE published on 02/11/2025 at 20:28, 1 year 7 months ago Inside Information / Other news releases Poxel announces results of its Combined General Meeting with approved resolutions on revised remuneration policy for corporate officers. Details available on company's website Voting Results Financial Press Release Combined General Meeting Poxel Remuneration Policy
BRIEF published on 01/31/2025 at 07:35, 1 year 7 months ago POXEL Announces Growing Sales of TWYMEEG in Japan for 2024 Poxel Sumitomo Pharma TWYMEEG Japan Sales 2024 Revenues
BRIEF published on 01/20/2025 at 07:35, 1 year 8 months ago POXEL Achieves Major Sales with TWYMEEG® in Japan Royalties TWYMEEG® Poxel Sumitomo Pharma Japan Sales
PRESS RELEASE published on 01/20/2025 at 07:30, 1 year 8 months ago Inside Information / Other news releases Poxel to receive sales-based payment and higher royalties from Sumitomo Pharma in Q1 2025 for TWYMEEG® achieving JPY 5 billion net sales in Japan. Positive results expected beyond 2024 fiscal year Royalties Poxel Sumitomo Pharma TWYMEEG Sales-based Payment
BRIEF published on 12/23/2024 at 07:35, 1 year 9 months ago Poxel Releases Half-Year Financial Report for 2024 Financial Report 2024 Biopharmaceutical Poxel Audit Review
Published on 09/23/2026 at 22:00, 4 hours 2 minutes ago Petrolympic Adopts Semi-Annual Financial Reporting
Published on 09/23/2026 at 18:25, 7 hours 37 minutes ago Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 10 hours 20 minutes ago Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 11 hours 31 minutes ago First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 11 hours 32 minutes ago Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Published on 09/23/2026 at 23:00, 3 hours 2 minutes ago Correction of a release from 23.09.2026 18:00 CET/CEST - MHM CORPORATE ANNOUNCES THE SUCCESS OF ITS CAPITAL INCREASE WITH PREFERENTIAL SUBSCRIPTION RIGHTS AND THE PARTIAL EARLY REDEMPTION OF BONDS REDEEMABLE IN SHARES
Published on 09/23/2026 at 19:51, 6 hours 11 minutes ago LIGHTON: LightOn renews its bond financing with the same financial partners for a maximum nominal amount of €4 million, and thus extends its cash flow horizon
Published on 09/23/2026 at 18:05, 7 hours 57 minutes ago XPRIZE Wildfire Awards $4.55M to Innovators Advancing Wildfire Detection and Response
Published on 09/23/2026 at 18:00, 8 hours 2 minutes ago ARVERNE GROUP: Release of the 2026 half-year financial report
Published on 09/23/2026 at 18:00, 8 hours 2 minutes ago ARVERNE GROUP: First half of 2026 60.1% growth in gross business volume to €16.8 million Operational performance above expectations
Published on 09/23/2026 at 19:14, 6 hours 48 minutes ago Robust performance from Investments and continued execution of the strategy
Published on 09/23/2026 at 17:45, 8 hours 17 minutes ago Report on share repurchases from 16 to 21 September 2026
Published on 09/23/2026 at 17:45, 8 hours 17 minutes ago Infotel : H1 2026 RESULTS. Revenue growth of +9.4%.
